You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 18, 2025

CLINICAL TRIALS PROFILE FOR FLUMAZENIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for FLUMAZENIL

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00262639 ↗ Prometa Protocol for Alcohol Dependence Completed Medical University of South Carolina Phase 2/Phase 3 2005-12-01 This is a placebo controlled trial (some people receive active and some people receive inactive medication) to evaluate the effectiveness of a new protocol to treat alcohol dependence. Two main medications (plus ancillary non-placebo controlled medications) and their placebos (inactive drugs) will be utilized to treat both alcohol withdrawal, promote abstinence, and reduce drinking over approximately a six-week treatment period. All participants will meet criteria for Alcohol Dependence and be drinking heavily up until 72 hours prior to receiving the first study drug. They will be injected one drug (flumazenil or placebo) over a two day period and receive the second one (gabapentin or placebo) by mouth for 39 days. The main hypothesis is that this protocol will reduce early alcohol withdrawal symptoms and will reduce relapse to drinking and promote abstinence compared to the placebo (inactive) drug group. Secondary outcomes that will be evaluated include reduction in craving, improvement in sleep, brain activity and mood.
NCT00176670 ↗ A GameBoy as a Distraction Before Surgery in Children Completed University of Medicine and Dentistry of New Jersey Phase 2 2004-01-01 Preoperative anxiety is characterized by subjective feelings of tension, apprehension, nervousness and worry. In children, preoperative anxiety is reported to result in postoperative negative psychological effects, including nightmares, separation anxiety, eating problems and increased fear of doctors. Anxiety in children can be expressed in many forms. Many children look scared, become agitated, breathe deeply, tremble, and stop talking or playing and start to cry. They may unexpectedly urinate or may actively attempt to escape from the medical personnel. These reactions reflect the child's fear of separation from the parents, as well as loss of control, unfamiliar routines, instruments and hospital procedures [1]. Previous studies have assessed anxiety in children during the preoperative period and the effects of premedication and parental presence during induction of anesthesia (PPIA) [2]. Midazolam has been proven to reduce preoperative anxiety in children [3]. Side effects related to oral midazolam administered to healthy children are minimal and the drug can be reversed with flumazenil but post operative recovery may be delayed in those children undergoing a short surgical procedure. It is the experience of the investigator that there are some children who have such low levels of anxiety they do not require any intervention Distraction may be particularly helpful in children ages 6-12 as these children may not receive preoperative medication due to their curiosity about the environment. Previous studies regarding distraction therapy have focused on the parent either blowing bubbles or reading to a child [4]. Studies where the child is actively engaged in a distraction activity have not been documented. The purpose of this investigation is to determine whether in the presence of a parent an interactive distraction intervention, i.e. Game Boy which is a hand held video game, is as effective as preoperative Midazolam in reducing preoperative anxiety. This study may help in the search for a low cost and easy to implement method of reducing anxiety for children undergoing surgery.
NCT00000246 ↗ Rapid Benzodiazepine Detoxification Using Flumazenil - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1993-01-01 The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.
NCT00000246 ↗ Rapid Benzodiazepine Detoxification Using Flumazenil - 1 Completed Yale University Phase 2 1993-01-01 The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for FLUMAZENIL

Condition Name

7333001234567RemimazolamAnxietyHealthyAnesthesia, General[disabled in preview]
Condition Name for FLUMAZENIL
Intervention Trials
Remimazolam 7
Anxiety 3
Healthy 3
Anesthesia, General 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

4332000.511.522.533.54DeliriumEmergence DeliriumAlcoholismPsychomotor Agitation[disabled in preview]
Condition MeSH for FLUMAZENIL
Intervention Trials
Delirium 4
Emergence Delirium 3
Alcoholism 3
Psychomotor Agitation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for FLUMAZENIL

Trials by Country

+
Trials by Country for FLUMAZENIL
Location Trials
United States 17
Korea, Republic of 15
China 12
Israel 2
Sweden 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for FLUMAZENIL
Location Trials
Connecticut 3
Michigan 2
California 2
Pennsylvania 2
South Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for FLUMAZENIL

Clinical Trial Phase

52.2%13.0%30.4%0012345678910111213Phase 4Phase 2/Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for FLUMAZENIL
Clinical Trial Phase Trials
Phase 4 12
Phase 2/Phase 3 1
Phase 2 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

43.2%27.3%22.7%6.8%02468101214161820CompletedNot yet recruitingRecruiting[disabled in preview]
Clinical Trial Status for FLUMAZENIL
Clinical Trial Phase Trials
Completed 19
Not yet recruiting 12
Recruiting 10
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for FLUMAZENIL

Sponsor Name

trials011223344Seoul National University HospitalSecond Affiliated Hospital of Nanchang UniversityAsan Medical Center[disabled in preview]
Sponsor Name for FLUMAZENIL
Sponsor Trials
Seoul National University Hospital 4
Second Affiliated Hospital of Nanchang University 4
Asan Medical Center 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

82.1%10.4%7.5%0-5051015202530354045505560OtherIndustryNIH[disabled in preview]
Sponsor Type for FLUMAZENIL
Sponsor Trials
Other 55
Industry 7
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Flumazenil: Clinical Trials, Market Analysis, and Projections

Introduction

Flumazenil, a benzodiazepine antagonist, is a crucial medication used to reverse the sedative effects of benzodiazepines, particularly in cases of overdose or after medical procedures involving anesthesia. Here, we will delve into the clinical aspects, market analysis, and future projections of flumazenil.

Clinical Use and Mechanism

Flumazenil is administered intravenously or intramuscularly and functions by competitively inhibiting the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the sedative effects of benzodiazepines[4].

Dosing and Administration

The typical dose of flumazenil is 0.01 mg/kg IV, with a maximum dose of 0.2 mg. If the desired level of consciousness is not achieved, repeat doses of 0.005–0.01 mg/kg IV can be administered at 45-second intervals. The induction time is usually 1–3 minutes, with peak effects observed between 6–10 minutes. However, the duration of effect is typically less than 60 minutes, which may necessitate repeated doses due to the longer duration of action of the benzodiazepine[1].

Clinical Considerations

Nursing Considerations

Re-sedation is a significant concern due to the shorter duration of action of flumazenil compared to benzodiazepines. Nurses must monitor patients closely and administer repeat doses as needed, typically at 20-minute intervals[1].

Precautions

Flumazenil should not be given to patients who are on benzodiazepines for seizure disorders, as it can precipitate seizures. It should also be used cautiously in patients on medications that lower the seizure threshold, such as tricyclic antidepressants, theophylline, isoniazid, or lithium[1].

Market Analysis

Current Market Size

The global flumazenil market was valued at approximately USD 73.38 million in 2023 and is expected to reach USD 76.39 million in 2024. By 2030, the market is projected to grow to USD 98.32 million, with a CAGR of 4.26%[5].

Market Drivers

The growth of the flumazenil market is driven by several factors:

  • Increasing Cases of Benzodiazepine Misuse and Overdoses: The rise in benzodiazepine misuse has led to a higher demand for reversal agents like flumazenil.
  • Growing Number of Surgical Procedures: The need for rapid and effective reversal of sedation in surgical settings contributes to market growth.
  • Rising Awareness Around Drug Safety: Efforts to reduce hospital recovery times and enhance patient safety also drive the demand for flumazenil[5].

Market Segmentation

The flumazenil market is segmented by route of administration, distribution channel, and region. North America, particularly the United States, accounts for a significant share of the market due to the high prevalence of anxiety disorders and the consequent use of benzodiazepines[3].

Future Projections

Market Growth

The market is expected to continue growing due to the increasing prevalence of anxiety disorders and the subsequent use of benzodiazepines. For instance, data from the Centers for Disease Control and Prevention shows an increase in symptoms of anxiety or depressive disorders among adults, which is likely to drive the demand for flumazenil[3].

Opportunities and Challenges

  • Expanding Applications: There are opportunities for expanding the use of flumazenil in pediatric and geriatric medicine, which could increase adoption rates.
  • Enhancing Delivery Mechanisms: Improving delivery mechanisms could also boost market growth.
  • Regulatory and Safety Considerations: Ensuring compliance with regulatory standards and addressing safety concerns will be crucial for market growth[5].

Key Players

The flumazenil market includes several key players such as Actavis, Apotex, Endo Pharmaceuticals, Fresenius Kabi, Fujifilm Holdings, and others. These companies are involved in various strategies including joint ventures and innovative product developments to strengthen their market presence[5].

Clinical Trials and Research

While there are no recent clinical trials specifically highlighted for flumazenil, ongoing research focuses on optimizing dosing regimens and exploring new applications. For example, studies on the use of flumazenil in different clinical settings, such as emergency medicine and critical care, continue to refine its clinical utility[1][4].

Side Effects and Safety Profile

Flumazenil can cause several side effects, including allergic reactions, changes in emotions or moods, confusion, fast heartbeat, seizures, and tremors. It is also important to note that flumazenil may precipitate withdrawal symptoms in opioid-dependent patients and should be used cautiously in patients with certain medical conditions such as head injury, heart disease, and lung or breathing diseases[4].

Key Takeaways

  • Clinical Use: Flumazenil is a benzodiazepine antagonist used to reverse sedation.
  • Market Size: The global flumazenil market is valued at USD 73.38 million in 2023 and is projected to reach USD 98.32 million by 2030.
  • Market Drivers: Increasing benzodiazepine misuse, growing surgical procedures, and rising awareness around drug safety drive market growth.
  • Future Projections: The market is expected to grow with opportunities in pediatric and geriatric medicine and enhanced delivery mechanisms.
  • Key Players: Several pharmaceutical companies are involved in the flumazenil market, focusing on innovative strategies and product developments.

FAQs

What is flumazenil used for?

Flumazenil is used to reverse the sedative effects of benzodiazepines, particularly in cases of overdose or after medical procedures involving anesthesia[4].

How is flumazenil administered?

Flumazenil is administered intravenously or intramuscularly, with a typical dose of 0.01 mg/kg IV and a maximum dose of 0.2 mg[1].

What are the potential side effects of flumazenil?

Potential side effects include allergic reactions, changes in emotions or moods, confusion, fast heartbeat, seizures, and tremors. It can also precipitate withdrawal symptoms in opioid-dependent patients[4].

What is the current market size of flumazenil?

The global flumazenil market was valued at approximately USD 73.38 million in 2023[5].

What are the key drivers of the flumazenil market?

Key drivers include increasing cases of benzodiazepine misuse and overdoses, growing number of surgical procedures, and rising awareness around drug safety[5].

Which regions are expected to drive the growth of the flumazenil market?

North America, particularly the United States, is expected to drive market growth due to the high prevalence of anxiety disorders and the consequent use of benzodiazepines[3].

Sources

  1. Department of Pediatrics: Reversal Agents - Department of Pediatrics.
  2. OpenPR: Flumazenil Market Size, Share, Development by 2025.
  3. The Brainy Insights: Flumazenil Market Size, Share, Trends, Global Forecast – 2030.
  4. Cleveland Clinic: Flumazenil injection.
  5. 360iResearch: Flumazenil Market by Route of Administration, Distribution Channel ...

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.